Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

Tapinarof Cream for Atopic Dermatitis: An Interim Analysis of Results in Adults, Children

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

Phase 3 Results on Upadacitinib for Atopic Dermatitis with Jonathan Silverberg, MD, PhD

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

3 Tried and True Methods of Pediatric Eczema Management

These data suggest that, among children with atopic dermatitis and ADHD or other learning disabilities, an assessment for impairment of their cognitive abilities may need prioritization.


Cognitive Evaluation Necessary Among Children with Eczema, Comorbid Neurodevelopmental Disorders 

These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.

Most Effective Atopic Dermatitis Treatments May Pose Greatest Risk of Adverse Events

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.


PH Labeling of Liquid Synthetic Detergents May Improve Outcomes for Atopic Dermatitis 

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

Abrocitinib Effective for Eczema Patients with Inadequate Response to Upadacitinib, Dupilumab

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

Biologics License Application for Nemolizumab Accepted by FDA for Prurigo Nodularis, Atopic Dermatitis

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

Lawrence Eichenfield, MD: Discussing New Findings on Topical Roflumilast for Atopic Dermatitis

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data. 

Roflumilast Topical Foam, 0.3% and Full STRATUM Results, with Andrew Blauvelt, MD, MBA

Atopic Dermatitis condition center page, resources on the topics of medical news and expert insight into eczema can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dermatitis research, treatment, and drug development.